Impact of geographic and cross-cultural differences on spontaneous adverse events reporting

Drug Information Journal

Volumn 33, Issue 3, 1999, Pages 921-931

  Wu, Hsiao Hui ^a   Fung, Man ^b   Hornbuckle, Ken ^b   Muniz, Edmundo ^b  

^a Intercontinental Region   (Taiwan)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cross cultural differences; Pharmacovigilance; Safety adverse event reporting; Spontaneous reporting system

Indexed keywords

AGE; ARTICLE; CANADA; CULTURAL FACTOR; DRUG ABUSE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG OVERDOSE; FRANCE; GEOGRAPHIC DISTRIBUTION; GERMANY; MORTALITY; PRIORITY JOURNAL; SELF REPORT; SEX DIFFERENCE; UNITED KINGDOM; UNITED STATES;

EID: 0032796942     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300333     Document Type: Article

References (31)

1. Johnson JM, Tanner LA. Postmarketing surveillance: curriculum for the clinical pharmacologist. Part II: Clinical and regulatory considerations. J Clin Pharmacol. 1993;33:1015-1022.
2. Piazza-Hepp TD, Kennedy DL. Reporting of adverse events to MedWatch. Am J Health-System Pharm. 1995;52:1436-1439.
3. Rossi AC, Knapp DE. Discovery of new adverse drug reactions: a review of the Food and Drug Administration's spontaneous reporting system. JAMA. 1984;252:1030-1033.
4. Sills JM, Tanner JA, Milstien JM. Food and Drug Administration monitoring of adverse drug reactions. Am J Hasp Pharm. 1986;43:2764-2770.
5. Strom BL, Melmon KL. Can postmarketing surveillance help to effect optimal drug therapy? JAMA. 1979;242:2420-2423.
6. Lortie FM. Postmarketing surveillance of adverse drug reactions: problems and solutions. Canadian Med Assoc J. 1986;135:27-32.
7. Moore N, Biour M, Paux G, et al. Adverse drug reaction monitoring: doing it the French way. Lancet. 1985;2:1056-1058.
8. Litovitz T. The TESS database. Use in product safety assessment. Drug Safety. 1998;18:9-19.
9. Finney DJ. The detection of adverse reactions to therapeutic drugs. Stat Med. 1982;1:153-161.
10. Rossi AC, Bosco L, Faich GA, Tanner LA. The importance of adverse reaction reporting by physicians. JAMA. 1988;259:1203-1204.
11. Clark JA, Zimmerman HJ, Tanner LA. Labetalol hepatotoxicity. Ann Intern Med. 1990;113:210-213.
12. Green L, Clark J. Fluoroquinolones and theophylline toxicity: Norfloxacin. JAMA. 1989;262:2383.
13. Jolson H, Tanner LA, Green L. Adverse reaction reporting of interactions between warfarin and fluoroquinolones. Arch Intern Med. 1991;151:1003-1004.
14. Belton KJ. Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union. The European Pharmacovigilance Research Group. European J Clin Pharmacol. 1997; 52:423-427.
15. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Pharmacolog Res. 1997;35:85-88.
16. Bateman DN, Sanders GL, Rawlins MD. Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol. 1992;34:421-426.
17. Generali JA, Danish MA, Rosenbaum SE. Knowledge of and attitudes about adverse drug reaction reporting among Rhode Island pharmacists. Ann Pharmacother. 1995;29:365-369.
18. Brenner MH. Economic change, alcohol consumption and heart disease mortality in nine industrialized countries. Soc Sci Med. 1987;25:119-132.
19. Griffin JP. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharmac. 1986;22(supplement):83S-100S.
20. Melnychuk D, Moride Y, Abenhaim L. Monitoring of drug utilization in public health surveillance activities: a conceptual framework. Can J Public Health. (Revue Canadienne de Sante Publique) 1993;84: 45-49.
21. Albengres E. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs. J Rheumatol. 1988;17(supplement):20-23.
22. Albengres E, Gauthier F, Tillement JP. Current French system of post-marketing drug surveillance. Int J Clin Pharmacol, Therapy, Toxicol. 1990;28: 312-314.
23. Kapp JF, Zentgraf R, Widmer A, Schopf E. A need to intensify drug surveillance in Germany. Klinische Wochenschrift. 1991;69:775-779.
24. Bem JL, Breckeridge AM, Mann Rd, Rawlins MD. Review of yellow cards (1986): report to the committee on the safety of medicines. Br J Clin Pharmac. 1988;26:679-689.
25. Smith CC, Bennett PM, Pearce Hm, et al. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol. 1996;42:423-429.
26. van Boxtel CJ, Wang G. Some observations on pharmacoepidemiology in Europe. Netherlands J Med. 1997;51:205-212.
27. Richard BW, Lasagna L. Drug regulation in the United States and the United Kingdom: the Depo-Provera story. Ann Int Med. 1987;106:886-891.
28. Baum C, Kennedy DL, Forbes MB, Jones JK. Drug use in the United States in 1981. JAMA. 1984;251: 1293-1297.
29. Raehl CL, Bond CA, Pitterle ME. Pharmaceutical services in U.S. hospitals in 1989. Am J Hosp Pharm. 1992;49:323-346.
30. O'Neil CK, Poirer TI. Impact of patient knowledge, patient-pharmacist relationship, and drug perceptions on adverse drug therapy outcomes. Pharmacother. 1998;18:333-340.
31. Poulton BC. Use of the consultation satisfaction questionnaire to examine patients' satisfaction with general practitioners and community nurses: reliability, replicability and disciminant validity. Br J General Practice. 1996;46:26-31.